Abbott Laboratories (FRA:ABL) Piotroski F-Score: 5 (As of Jun. 26, 2026) — 17% Below Median


FRA:ABL Abbott Laboratories FRA:ABL
80 GF Score
Price €82.24
GF Value €114.21
Valuation Modestly Undervalued
View Full Analysis

What is Abbott Laboratories Piotroski F-Score?

Abbott Laboratories FRA:ABL +2.95% 80 Piotroski F-Score is 5 as of Jun. 26, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates FRA:ABL with a GF Score™ of 80/100 and a GF Value™ of €114.21 (Modestly Undervalued). Among 805 Medical Devices & Instruments companies, Abbott Laboratories ranks better than 64.97% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Abbott Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Abbott Laboratories's Piotroski F-Score or its related term are showing as below:

FRA:ABL' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Abbott Laboratories was 9. The lowest was 5. And the median was 6.

Abbott Laboratories  (FRA:ABL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Abbott Laboratories Piotroski F-Score Related Terms


Abbott Laboratories Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Piotroski F-Score Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.00 5.00 6.00 8.00 5.00

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 5.00 5.00

FRA:ABL vs SYK, MDT, BSX: Piotroski F-Score Comparison

For the Medical Devices subindustry, Abbott Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Piotroski F-Score falls into.


FRA:ABL
80GF Score
Abbott Laboratories FRA:ABL
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 1542.393 + 1400.688 + 1516.704 + 931.605 = €5,391 Mil.
Cash Flow from Operations was 1774.749 + 2374.524 + 2831.01 + 1137.475 = €8,118 Mil.
Revenue was 9660.114 + 9686.388 + 9785.986 + 9656.86 = €38,789 Mil.
Gross Profit was 5451.696 + 5362.488 + 5582.598 + 5427.01 = €21,824 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(75339.4 + 72827.133 + 71722.212 + 74052.902 + 95521.085) / 5 = €77892.5464 Mil.
Total Assets at the begining of this year (Mar25) was €75,339 Mil.
Long-Term Debt & Capital Lease Obligation was €25,637 Mil.
Total Current Assets was €22,064 Mil.
Total Current Liabilities was €15,896 Mil.
Net Income was 1209.558 + 1483.046 + 8813.695 + 1225.625 = €12,732 Mil.

Revenue was 9640.233 + 9582.135 + 10480.17 + 9581.15 = €39,284 Mil.
Gross Profit was 5364.046 + 5349.237 + 5760.56 + 5448.25 = €21,922 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(66669.64 + 67832.793 + 66994.756 + 77750.37 + 75339.4) / 5 = €70917.3918 Mil.
Total Assets at the begining of last year (Mar24) was €66,670 Mil.
Long-Term Debt & Capital Lease Obligation was €11,781 Mil.
Total Current Assets was €21,417 Mil.
Total Current Liabilities was €12,029 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Abbott Laboratories's current Net Income (TTM) was 5,391. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Abbott Laboratories's current Cash Flow from Operations (TTM) was 8,118. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=5391.39/75339.4
=0.07156136

ROA (Last Year)=Net Income/Total Assets (Mar24)
=12731.924/66669.64
=0.19097034

Abbott Laboratories's return on assets of this year was 0.07156136. Abbott Laboratories's return on assets of last year was 0.19097034. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Abbott Laboratories's current Net Income (TTM) was 5,391. Abbott Laboratories's current Cash Flow from Operations (TTM) was 8,118. ==> 8,118 > 5,391 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=25636.87/77892.5464
=0.32913124

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=11780.8/70917.3918
=0.16612004

Abbott Laboratories's gearing of this year was 0.32913124. Abbott Laboratories's gearing of last year was 0.16612004. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=22064.42/15896.105
=1.3880394

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=21416.525/12028.7
=1.78045217

Abbott Laboratories's current ratio of this year was 1.3880394. Abbott Laboratories's current ratio of last year was 1.78045217. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Abbott Laboratories's number of shares in issue this year was 1747.073. Abbott Laboratories's number of shares in issue last year was 1747.22. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=21823.792/38789.348
=0.56262333

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=21922.093/39283.688
=0.5580457

Abbott Laboratories's gross margin of this year was 0.56262333. Abbott Laboratories's gross margin of last year was 0.5580457. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=38789.348/75339.4
=0.51486139

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=39283.688/66669.64
=0.58922904

Abbott Laboratories's asset turnover of this year was 0.51486139. Abbott Laboratories's asset turnover of last year was 0.58922904. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Abbott Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Abbott Laboratories (FRA:ABL) has a Piotroski F-Score of 5 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Abbott Laboratories and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Abbott Laboratories' Piotroski F-Score has ranged from 5.00 to 9.00. According to the industry distribution chart, Abbott Laboratories ranks #282 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is Abbott Laboratories' Piotroski F-Score too high?
Abbott Laboratories' current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 9.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Abbott Laboratories' value of 5 is 0% at this industry median. Based on the distribution chart, Abbott Laboratories ranks #282 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Piotroski F-Score compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #282 out of 805 companies for Piotroski F-Score. This puts Abbott Laboratories in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Abbott Laboratories' value of 5 is 0% at this benchmark. Historically, Abbott Laboratories' own Piotroski F-Score has ranged from 5.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Abbott Laboratories has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (FRA:ABL) is currently considered Modestly Undervalued. The stock's GF Value™ is €114.21, compared to a current price of €82.24 — trading 28% below its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Medical Devices & Instruments industry median of 5.00. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Abbott Laboratories (FRA:ABL), the current Piotroski F-Score is 5 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (FRA:ABL) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of €82.24 is trading 28% below its estimated GF Value™ of €114.21. GuruFocus considers Abbott Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:ABL:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: €114.21 vs. price of €82.24 (28% below fair value)
  • GF Score™: 80/100
  • Industry Position: 0% at the Medical Devices & Instruments median (#282 of 805)

No single metric tells the full story. See the FRA:ABL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score

Get the complete analysis for FRA:ABL

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.24
Price
€114.21
GF Value